Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy

被引：9

作者：

Poveda, Eva

Briz, Veronica

Paraskevis, Dimitrios

Barreiro, Pablo

Hatzakis, Angelos

Soriano, Vincent

机构：

[1] Hosp Carlos III, Dept Infect Dis, Madrid 28029, Spain

[2] Univ Athens, Sch Med, Dept Infect Dis, GR-11527 Athens, Greece

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2007年 / 23卷 / 09期

关键词：

D O I：

10.1089/aid.2006.0287

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Genetic analysis of HIV-1 gp41 in plasma and peripheral blood mononuclear cell (PBMC) compartments was performed longitudinally in 10 HIV-infected patients treated with enfuvirtide. The appearance of enfuvirtide resistance mutations in PBMCs (DNA) generally occurred after (from 23 to 157 weeks) being recognizable in plasma (RNA). The disappearance of drug-resistant HIV-1 mutations to enfuvirtide in seven patients who discontinued the drug was directly dependent of the exposure time failing enfuvirtide, being associated mainly with the selection of secondary/compensatory mutations recognizable in proviral DNA.

引用

页码：1078 / 1082

页数：5

共 50 条

[1] Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
Lazzarin, A
Clotet, B
Cooper, D
Reynes, J
Arasteh, K
Nelson, M
Katlama, C
Stellbrink, H
Delfraissy, J
Lange, J
Huson, L
DeMasi, R
Wat, C
Delehanty, J
Drobnes, C
Salgo, M
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22): : 2186 - 2195
[2] Distribution of drug-resistant HIV-1 variants in plasma RNA and peripheral blood monuclear cell DNA in patients on therapy and after treatment interruption
Romano, L
Venturi, G
Carli, T
Corsi, P
Pippi, L
Valensin, PE
Zazzi, M
ANTIVIRAL THERAPY, 2002, 7 : S122 - S122
[3] Drug-resistant genotyping in HIV-1 therapy
Zöllner, B
Feucht, HH
Weitner, L
Adam, A
Laufs, R
LANCET, 1999, 354 (9184): : 1120 - 1121
[4] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
Lalezari, JP
Henry, K
O'Hearn, M
Montaner, JSG
Piliero, PJ
Trottier, B
Walmsley, S
Cohen, C
Kuritzkes, DR
Eron, JJ
Chung, J
DeMasi, R
Donatacci, L
Drobnes, C
Delehanty, J
Salgo, M
Farthing, C
Graham, E
Packard, M
Ngo, L
Lederman, M
Buam, J
Pollard, R
Rauf, S
Silkowski, W
Thompson, M
Rucker, A
Harris, M
Larsen, G
Preseon, S
Cunningham, D
Guimaraes, D
Bertasso, A
Kinchelow, T
Myers, R
Phoenix, BCBP
Skolnik, PR
Adams, B
Leite, OHM
Oliveira, M
Lefebvre, E
Gomez, B
Foy, KB
Lampiris, H
Charles, S
Dobkin, J
Crawford, M
Slom, T
Murphy, R
Mikaitis, T
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22): : 2175 - 2185
[5] Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management
Bon, Isabella
Alessandrini, Federica
Borderi, Marco
Gorini, Roberta
Re, Maria Carla
NEW MICROBIOLOGICA, 2007, 30 (03): : 313 - 317
[6] Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?
Frenkel, LM
Mullins, JI
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07): : 520 - 522
[7] Consistency of drug-resistant mutations in plasma and peripheral blood mononuclear cells of patients with treatment-naïve and treatment-experienced HIV-1 infection
Ma, Jie
Chen, Zhaoyun
Fu, Chaohong
Wei, Shuguang
Liu, Jinjin
Yang, Xuan
Chen, Xuhui
Zhao, Qingxia
Sun, Yan
Huo, Yuqi
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
[8] Persistence of drug-resistant HIV-1 and possible implications for antiretroviral therapy
Metzner, Karin J.
FUTURE VIROLOGY, 2006, 1 (03) : 377 - 391
[9] Epidemiology of drug-resistant HIV-1 transmission in naive patients in Spain
Yebra, Gonzalo
Holguin, Africa
MEDICINA CLINICA, 2010, 135 (12): : 561 - 567
[10] Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy
Venturi, G
Romano, L
Carli, T
Corsi, P
Pippi, L
Valensin, PE
Zazzi, M
ANTIVIRAL THERAPY, 2002, 7 (04) : 245 - 250

← 1 2 3 4 5 →